HUM sits at a crossroads as Medicare Advantage pressures cap near-term upside, but resilience versus peers argues for patience, not panic.
| Quartal / Datum | EPS (USD) | Schätzung (USD) | Abweichung |
|---|
| Quartal / Datum | Umsatz (Mrd USD) | Schätzung (Mrd USD) | Abweichung |
|---|